ESR1 and breast carcinoma: Due to the characteristic of a higher turnover rate and greater homeostasis demand of ERα protein in breast cancer cells, ERα-targeting DUBs have become critical targets for novel cancer therapeutics discovery (Xiao et al, 2016).